MARLBOROUGH, Mass., July 11, 2018 /CNW/ -- Hologic's (Nasdaq: HOLX) Cynosure division announced today the North American launch of TempSure™ Vitalia, an FDA-cleared and Health Canada-approved advanced ...

Marlborough medical device maker Hologic is expecting revenues from subsidiary Cynosure to be about $15 million less after it halted sales of a device due to a government warning. Westford-based ...

(RTTNews) - Hologic Inc.'s (HOLX) Cynosure division said it has launched TempSure Vitalia, an FDA-cleared and Health Canada-approved advanced radiofrequency treatment, in North America. Hologic noted ...

Shares of Hologic Inc. fell 2.9% in premarket trade Monday, after the company said its Cynosure division will suspend marketing and distribution of its Vitalia TempSure device for heating of vaginal ...

Leading player in the field of women's health, Hologic, Inc. HOLX recently announced that its Cynosure division has launched the FDA-approved TempSure Surgical RF technology in North America. Notably, ...

Hologic, Inc.’s Cynosure division announced today the North American launch of the FDA-cleared TempSure ™ Surgical RF technology, a new offering of the TempSure ™ radiofrequency (RF) platform that ...

The TempSure ™ Vitalia treatment, administered using a probe specifically designed for women's genitalia, delivers precise heating for smaller, hard-to-reach areas such as vaginal and labial tissue, ...